Table 1 lists the clinical characteristics and oncologic outcomes of the 23 patients included in this SB 225002 study. Overall, 13 (56.5%), 8 (34.8%), and 2 (8.7%) patients had PS IIA (pN1), IIB (pN2), and IIC (pN3) disease, respectively. The 5-year DFS of entire cohort irrespective of PS was 100% with a median follow-up of 5.8 years (range, 2.1-25.4). DFS was not significantly different comparing PS IIA vs IIB/IIC disease (see Fig. 1). There were 2 recurrences (14%), and both were late relapses diagnosed by elevated tumor markers during follow-up. One patient with PS IIA disease had a pelvic recurrence 11 years after primary RPLND. The final pathology of the pelvic mass demonstrated embryonal carcinoma. He is skeletal system currently free of disease 2 years after his second surgery without adjuvant chemotherapy. The second patient with PS IIB disease had a right modified RPLND initially and developed elevated alpha-fetal protein and a solitary left-sided retroperitoneal recurrence 10 years after his surgery. He was given cisplatinum-based chemotherapy followed by a recent postchemotherapy RPLND on the left side. Final pathology demonstrated mixed NSGCT with yolk-sac tumor and teratoma.